ReviewGastroenterology report2015
Optimizing the use of biological therapy in patients with inflammatory bowel disease.
Review in Gastroenterology report, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Dose Escalation Patterns of Advanced Therapies in Crohn's Disease and Ulcerative Colitis: A Systematic Literature Review.Advances in therapy · 2023Pooled it
- Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2017Pooled it
- Pooled it
- Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach-an Indian experience.European journal of clinical pharmacology · 2021Trial
- Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study.Inflammatory bowel diseases · 2016Trial
- A Pilot Study of the Real-World Impact of Digital Cognitive Behavioral Therapy for Inflammatory Bowel Disease (COMPASS-IBD) on Inflammation, Disease Activity, and Healthcare Use.Biopsychosocial science and medicine · 2026Article
- Psychological distress predicts disease activity in inflammatory bowel disease: Results from the mind-body IBD longitudinal study.Brain, behavior, & immunity - health · 2026Article
- A single-cell atlas of ulcerative colitis reveals neutrophil-stromal circuits linked to biologic therapy resistance.Frontiers in immunology · 2026Article
- Melatonin, an Antitumor Necrosis Factor Therapy.Journal of pineal research · 2025Review
- Study of tumor necrosis factor receptor in the inflammatory bowel disease.World journal of gastroenterology · 2023Review
- IL-1 and CD40/CD40L platelet complex: elements of induction of Crohn's disease and new therapeutic targets.Archives of pharmacal research · 2021Review
- A Machine Learning Model Accurately Predicts Ulcerative Colitis Activity at One Year in Patients Treated with Anti-Tumour Necrosis Factor α Agents.Medicina (Kaunas, Lithuania) · 2020Article
- Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassays.Therapeutic advances in gastroenterology · 2020Article
- Influence of the Treatment Used in Inflammatory Bowel Disease on the Protease Activities.International journal of general medicine · 2020Article
- Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data.Alimentary pharmacology & therapeutics · 2020Article
- Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease.Gut and liver · 2019Article
- Trends and Factors Associated with Hospitalization Costs for Inflammatory Bowel Disease in the United States.Applied health economics and health policy · 2019Article
- Evaluating the clinical and economic consequences of using video capsule endoscopy to monitor Crohn's disease.Clinical and experimental gastroenterology · 2019Article
- Accuracy of the new rapid test for monitoring adalimumab levels.Therapeutic advances in gastroenterology · 2019Article
- Biologic treatment of Japanese patients with inflammatory bowel disease.BMC gastroenterology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biological therapy revolutionized the treatment of inflammatory bowel disease (IBD) during the last decade. These monoclonal antibodies, which target tumor necrosis factor (TNF), integrins or IL12/23, have been approved-or are in development for-both Crohn's disease (CD) and ulcerative colitis (UC). Early use of these agents taught clinicians that induction and maintenance therapy, coupled with immunomodulator agents, reduced the immunogenicity of these agents, and led to sustained remission in many patients. More recent data has demonstrated that, through dose adjustments, optimizing serum drug levels may also provide more durable maintenance of remission, and improved mucosal healing. This review examines clinical practices that may enhance clinical outcomes from biological therapy in IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.